Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, tisotumab vedotin-tftv, for the treatment of patients ...

Zai Lab (ZLAB – Research Report) received a Buy rating and a $55.00 price target from Scotiabank analyst Louise Chen today. The company’s shares opened today at $35.16. See what stocks are ...

Learn more about whether Exact Sciences Corporation or Zai Lab Limited is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.